search
Back to results

Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts

Primary Purpose

Aortic Aneurysm, Thoracoabdominal, Aortic Aneurysm, Thoracic, Aortic Dissection, Thoracoabdominal

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Endovascular treatment of Thoracoabdominal Aortic Aneurysm
Endovascular treatment of Aortic Arch Aneurysms
Sponsored by
Darren Schneider, M.D.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Aortic Aneurysm, Thoracoabdominal focused on measuring Thoracoabdominal, Aneurysm, Endovascular, Stent-Graft, Aortic Arch, BEVAR, FEVAR, Aorta, Aortic Dissection

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

TAAA STUDY ARM

Inclusion Criteria:

  1. Presence of TAAA in:

    1. Men with TAAA greater than or equal to 6 cm in diameter
    2. Women with TAAA greater than or equal to 5 cm in diameter
    3. Men with TAAA larger than 5 cm in diameter and enlarging at a rate of more than 10mm/year
    4. Women with TAAA larger than 4.5 cm in diameter and enlarging at a rate of more than 10mm/year or
    5. Men or women with TAAA and an iliac artery aneurysm greater than or equal to 4 cm in diameter
  2. Life expectancy more than 2 years
  3. Ability to give informed consent, complete pre-treatment assessments and comply with the follow-up schedule per protocol
  4. Suitable arterial anatomy for endovascular TAAA repair with "TAAA device":

    1. Proximal aortic landing zone:

      • ≥ 20mm long
      • ≤ 40mm and ≥ 20mm diameter in parallel aorta
      • free from circumferential thrombus
      • ≤ 60 degrees angulation
    2. Mesenteric/renal aortic diameter ≥ 20mm
    3. Mesenteric arteries:

      • ≥ 10mm long segment of healthy artery for branch attachment
      • Diameter ≥ 4mm and ≤ 12mm
      • Absence of aberrant or early branching, aneurysm or dissection
    4. Renal arteries:

      • ≥ 10mm long segment of healthy artery for branch attachment
      • Diameter ≥ 4mm and ≤ 8mm
      • Absence of aberrant or early branching, aneurysm or dissection
    5. Iliac artery access:

      • ≥ 6mm diameter, and absence of severe calcification and tortuosity
      • Or, planned creation of surgical conduit for TAAA device delivery
    6. For patients with associated common iliac artery aneurysms (>20mm diameter), adequate internal and external iliac artery landing zones and common iliac artery luminal diameter (for iliac branch device use):

      • ≥ 10mm long segment of healthy internal iliac artery for branch attachment
      • Internal iliac diameter ≥ 5mm and ≤ 12mm
      • External iliac diameter ≥ 6mm diameter, and absence of severe calcification and tortuosity
      • Minimum common iliac artery luminal diameter ≥ 14mm
      • Or, in patients with bilateral common iliac artery aneurysms without suitable anatomy, planned surgical bypass to maintain patency of at least one internal iliac artery
  5. Patients deemed high risk for open repair (meeting one, or more, of the following criteria):

    1. Age ≥ 65 year
    2. Cardiac disease:

      • CAD (history of MI or angina with positive stress test and not revascularizable)
      • LV Ejection fraction < 40%
      • Symptomatic CHF (NYHC Class II, III, or IV)
    3. Pulmonary disease:

      • Home oxygen therapy
      • FEV1 < 1.2 l/s
      • Vital capacity < 50% predicted
      • PaCO2 > 45 mm Hg or < 60 mm Hg
    4. Renal disease:

      • ESRD on dialysis
      • eGFR < 60
    5. Prior aortic surgery
    6. Hostile abdomen
    7. Portal hypertension (ascites or varices)
    8. Coagulopathy

AORTIC ARCH STUDY ARM

Inclusion Criteria:

  1. Presence of aortic arch aneurysm in:

    1. Men with aortic arch aneurysm greater than or equal to 6 cm in diameter, or
    2. Women with aortic arch aneurysm greater than or equal to 5 cm in diameter, or
    3. Men with aortic arch aneurysm larger than 5 cm in diameter and enlarging at a rate of more than 10 mm/year, or
    4. Women with aortic arch aneurysm larger than 4.5 cm in diameter and enlarging at a rate of more than 10 mm/year, or
    5. Saccular aortic arch aneurysms deemed at significant risk for rupture based upon physician interpretation
  2. Life expectancy more than 2 years
  3. Ability to give informed consent, complete pre-treatment assessments and comply with the follow-up schedule per protocol.
  4. Suitable arterial anatomy for endovascular aortic arch repair with "Aortic Arch Device":

    1. Aneurysm of the aortic arch beginning distal to the native coronary arteries or any patent coronary artery bypass
    2. Proximal aortic landing zone:

      • Native aorta or surgical graft
      • ≥ 20 mm long
      • ≤ 42 mm and ≥ 20 mm diameter in parallel aorta
      • free from circumferential thrombus
    3. Distal aortic landing zone:

      • Native aorta or surgical graft
      • ≥ 20 mm long
      • ≤ 42 mm and ≥ 20 mm diameter in parallel aorta
      • free from circumferential thrombus
      • ≥ 50mm length from native coronary arteries or patent coronary bypass graft to innominate artery
    4. Adequate supra-aortic trunk branch landing zone(s):

      • Innominate artery (if applicable):

        • Native vessel or surgical graft
        • Diameter: 8-22mm
        • Length of sealing zone ≥10mm
        • Acceptable tortuosity
        • Absence of dissection in landing zone
      • Left (or right) common carotid artery (if applicable):

        • Native vessel or surgical graft
        • Diameter 6-16mm
        • Length of sealing zone ≥10mm
        • Acceptable tortuosity
        • Absence of dissection in landing zone
      • Left (or right) subclavian artery (if applicable):

        • Native vessel or surgical graft
        • Diameter: 5-20mm
        • Length of sealing zone ≥10mm
        • Acceptable tortuosity
        • Absence of dissection in landing zone
    5. Iliac artery access:

      • ≥ 6mm diameter, and absence of severe calcification and tortuosity
      • Or, planned creation of surgical conduit for TAAA device delivery
  5. Patients deemed high risk for open surgical aortic arch repair based upon consensus of both a qualified cardiac surgeon and a qualified vascular surgeon and meeting one, or more, of the following criteria):

    1. Age > 70 years-old
    2. Prior ascending or aortic arch repair
    3. Multiple (≥2) median sternotomies
    4. Ischemic cardiomyopathy with multi-level coronary artery disease and/or positive stress test
    5. Chronic pulmonary disease with FEV1 < 1500ml
    6. Chronic kidney disease with eGFR ≤ 60 ml/kg/hr
    7. Large aneurysm abutting the sternotomy
    8. Severe deconditioning or immobility
    9. Prior cervical irradiation
    10. Other medical condition associated with prohibitive high risk with open repair based upon multidisciplinary consensus (cardiac surgery and vascular surgery)

APPLIES TO BOTH STUDY ARMS

Exclusion Criteria:

  1. Rupture, with hypotension (systolic bp < 90).
  2. Pregnancy or breastfeeding.
  3. Unwillingness or inability to comply with the follow up schedule.
  4. Serious systemic or groin infection.
  5. Uncorrectable coagulopathy.
  6. Age < 18 years.
  7. Mycotic or ruptured aneurysm.
  8. Known degenerative connective tissue disease, e.g., Marfan or Ehler-Danlos Syndrome (unless proximal implantation is into a previously placed surgical graft).
  9. Known sensitivities or allergies to stainless steel, nitinol, polyester, solder (tin, silver), polypropylene, urethane or gold.
  10. Participation in another in another investigational device or drug study within 1 year of treatment.
  11. Unrelated concomitant major surgical or interventional procedure(s) within 30 days of treatment date (with the exception of staged procedures planned as part of treatment)
  12. Body habitus that would inhibit X-ray visualization of the aorta.
  13. Acute aortic dissection

Sites / Locations

  • New York Presbyterian Hospital
  • Hospital of the University of PennsylvaniaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

TAAA (thoracoabdominal aortic aneurysm) Study Arm

Aortic Arch Study Arm

Arm Description

Either the Off-the-Shelf TAAA device or the Physician-Specified TAAA Device will be implanted. The Off-the-Shelf TAAA Device is a standard configuration Zenith t-Branch with four branches for the mesenteric arteries and the renal arteries. The Physician-Specified TAAA Devices may include a combination of up to 5 fenestrations and branches for mesenteric and renal arteries. Branches will be used for downward-oriented mesenteric and renal arteries and fenestrations for renal arteries that project laterally or upwards.

Physician-specified double inner branch stent-graft with or without retrograde left subclavian branch or a physician-specified retrograde left subclavian branch stent-graft with double or triple wide scallop to the left common carotid artery.

Outcomes

Primary Outcome Measures

Technical Success
Successful deployment of the TAAA device or Physician-Specified TAAA Devices, or Aortic Arch device & bridging covered stents into all targeted mesenteric & renal, or supra-aortic arteries with stent-graft & all branches patent by intraop angiography
Procedural Success
Technical success plus freedom from type I or III endoleak, loss of target vessel patency, death, major stroke, paralysis, new onset permanent hemodialysis, major amputation, & bowel infarction following deployment of the branched stent-graft.
Freedom from aneurysm-related mortality at 1 year
Survival from aneurysm-related death.
Treatment success at 12 months post-procedure
Composite endpoint which includes Technical Success, Procedural Success, and freedom from aneurysm-related mortality

Secondary Outcome Measures

Target artery patency
Imaging studies (CT Scans, Ultrasound and/or x-rays) are completed yearly to evaluate target artery patency.
Freedom from all-cause mortality
Clinical evaluations are completed yearly and include bloodwork (WBC, Hemoglobin, Hematocrit, Platelets, BUN [Urea Nitrogen], Creatinine, eGFR), imaging scans (CT scans, Ultrasounds, and/or x-rays) and adverse event evaluation.
Freedom from reintervention
Clinical evaluations are completed yearly and include bloodwork (WBC, Hemoglobin, Hematocrit, Platelets, BUN [Urea Nitrogen], Creatinine, eGFR), imaging scans (CT scans, Ultrasounds, and/or x-rays) and adverse event evaluation to determine if reintervention with the device is necessary.
Freedom from endoleak
Imaging studies (CT Scans, Ultrasound and/or x-rays) are completed yearly to evaluate device integrity and any device leaks.
Freedom from aneurysm dilatation
Imaging studies (CT Scans, Ultrasound and/or x-rays) are completed yearly to evaluate aneurysm size.
Freedom from serious adverse events (SAE) and major complications
Clinical evaluations are completed yearly and include bloodwork (WBC, Hemoglobin, Hematocrit, Platelets, BUN [Urea Nitrogen], Creatinine, eGFR), imaging scans (CT scans, Ultrasounds, and/or x-rays) and adverse event evaluation.
Freedom from aneurysm rupture and conversion to open repair
Clinical evaluations are completed yearly and include bloodwork (WBC, Hemoglobin, Hematocrit, Platelets, BUN [Urea Nitrogen], Creatinine, eGFR), imaging scans (CT scans, Ultrasounds, and/or x-rays) and adverse event evaluation to determine if aneurysm stability.
Freedom from stent graft migration and branch device migration
Imaging studies (CT Scans, Ultrasound and/or x-rays) are completed yearly to evaluate device integrity and any device leaks.
Freedom from major stroke
Clinical evaluations are completed yearly and include bloodwork (WBC, Hemoglobin, Hematocrit, Platelets, BUN [Urea Nitrogen], Creatinine, eGFR), imaging scans (CT scans, Ultrasounds, and/or x-rays) and adverse event evaluation.
Freedom from paralysis
Clinical evaluations are completed yearly and include bloodwork (WBC, Hemoglobin, Hematocrit, Platelets, BUN [Urea Nitrogen], Creatinine, eGFR), imaging scans (CT scans, Ultrasounds, and/or x-rays) and adverse event evaluation.
Freedom from onset permanent hemodialysis
Clinical evaluations are completed yearly and include bloodwork (WBC, Hemoglobin, Hematocrit, Platelets, BUN [Urea Nitrogen], Creatinine, eGFR), imaging scans (CT scans, Ultrasounds, and/or x-rays) and adverse event evaluation.
Freedom from amputation
Clinical evaluations are completed yearly and include bloodwork (WBC, Hemoglobin, Hematocrit, Platelets, BUN [Urea Nitrogen], Creatinine, eGFR), imaging scans (CT scans, Ultrasounds, and/or x-rays) and adverse event evaluation.
Freedom from bowel infarction
Clinical evaluations are completed yearly and include bloodwork (WBC, Hemoglobin, Hematocrit, Platelets, BUN [Urea Nitrogen], Creatinine, eGFR), imaging scans (CT scans, Ultrasounds, and/or x-rays) and adverse event evaluation.
Freedom from loss of target vessel patency
Imaging studies (CT Scans, Ultrasound and/or x-rays) are completed yearly to evaluate device integrity and any device leaks.

Full Information

First Posted
December 18, 2014
Last Updated
October 18, 2023
Sponsor
Darren Schneider, M.D.
search

1. Study Identification

Unique Protocol Identification Number
NCT02323581
Brief Title
Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts
Official Title
Feasibility, Safety, and Clinical Outcomes of Endovascular Treatment of Thoracoabdominal Aortic Aneurysms and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 2013 (Actual)
Primary Completion Date
December 2028 (Anticipated)
Study Completion Date
December 2033 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Darren Schneider, M.D.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Prospective, nonrandomized, single-center, two-arm study to assess the feasibility and safety and to evaluate clinical outcomes of endovascular repair of complex aortic aneurysms (thoracoabdominal aortic aneurysms and aortic arch aneurysms) in patients at high risk for open surgery.
Detailed Description
To assess the feasibility and safety and to evaluate clinical outcomes of endovascular repair of complex aortic aneurysms (thoracoabdominal aortic aneurysms and aortic arch aneurysms) in patients at high risk for open surgery in two study arms: TAAA (thoracoabdominal aortic aneurysm) Study Arm: To assess the feasibility and safety and to evaluate clinical outcomes of endovascular stent graft implantation using either a multibranched stent graft (Off-the-Shelf TAAA Device) or custom-manufactured physician-specified branched and/or fenestrated stent graft (Physician-Specified TAAA Device) to treat aortic aneurysms involving the mesenteric and/or renal arteries (TAAA) in patients at high risk for open surgery. Aortic Arch Study Arm: To assess the feasibility and safety and to evaluate clinical outcomes of endovascular stent graft implantation using a physician-specified aortic arch stent graft device [1) double inner branch stent-graft with or without retrograde left subclavian branch or 2) a physician-specified retrograde left subclavian branch stent-graft with double or triple wide scallop to the left common carotid artery] to treat aortic aneurysms involving the aortic arch in patients at high risk for open surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Aortic Aneurysm, Thoracoabdominal, Aortic Aneurysm, Thoracic, Aortic Dissection, Thoracoabdominal
Keywords
Thoracoabdominal, Aneurysm, Endovascular, Stent-Graft, Aortic Arch, BEVAR, FEVAR, Aorta, Aortic Dissection

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
370 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
TAAA (thoracoabdominal aortic aneurysm) Study Arm
Arm Type
Experimental
Arm Description
Either the Off-the-Shelf TAAA device or the Physician-Specified TAAA Device will be implanted. The Off-the-Shelf TAAA Device is a standard configuration Zenith t-Branch with four branches for the mesenteric arteries and the renal arteries. The Physician-Specified TAAA Devices may include a combination of up to 5 fenestrations and branches for mesenteric and renal arteries. Branches will be used for downward-oriented mesenteric and renal arteries and fenestrations for renal arteries that project laterally or upwards.
Arm Title
Aortic Arch Study Arm
Arm Type
Experimental
Arm Description
Physician-specified double inner branch stent-graft with or without retrograde left subclavian branch or a physician-specified retrograde left subclavian branch stent-graft with double or triple wide scallop to the left common carotid artery.
Intervention Type
Device
Intervention Name(s)
Endovascular treatment of Thoracoabdominal Aortic Aneurysm
Intervention Description
A TAAA is an abnormal enlargement (ballooning out) of the main artery (the aorta) and involves all or part of the aorta in your chest as well as all or part of the aorta in the abdomen. It also involves the part of the aorta where the arteries that bring blood to the liver, stomach and intestines and kidneys are attached. This investigational procedure that is being studied uses stent-grafts (cylindrical fabric tubes (grafts), with metal springs (stents) attached). The stent-grafts are placed inside the aneurysmal (weakened) area of the aorta to re-line it. These customized stent-grafts have special branches attached to them or openings (called "fenestrations") that are used to keep blood flowing to the arteries that supply the liver, stomach, intestines and kidneys. The investigational stent graft will be designed and custom-made specifically for your aneurysm.
Intervention Type
Device
Intervention Name(s)
Endovascular treatment of Aortic Arch Aneurysms
Intervention Description
An aortic arch aneurysm is an abnormal enlargement (ballooning out) of the main artery (the aorta). The ascending aorta and aortic arch is the first part of the vessel as it exits the heart and makes a turn around the area of the collar bone. This part of the aorta gives branches that supply the head, brain and arms. The arch branch endovascular graft includes the main aortic arch portion and one to three cuffs (side branches) that allow the graft to be located in the aortic arch. The number of cuffs is decided based on the anatomy of your aneurysm. The arteries in the aortic arch are the innominate artery (Zone 0), left common carotid artery (Zone 1) and the left subclavian artery (Zone 2). These arteries supply the right arm and right side of the brain, the left side of the brain and the left arm, respectively.
Primary Outcome Measure Information:
Title
Technical Success
Description
Successful deployment of the TAAA device or Physician-Specified TAAA Devices, or Aortic Arch device & bridging covered stents into all targeted mesenteric & renal, or supra-aortic arteries with stent-graft & all branches patent by intraop angiography
Time Frame
Intraoperative
Title
Procedural Success
Description
Technical success plus freedom from type I or III endoleak, loss of target vessel patency, death, major stroke, paralysis, new onset permanent hemodialysis, major amputation, & bowel infarction following deployment of the branched stent-graft.
Time Frame
30 days
Title
Freedom from aneurysm-related mortality at 1 year
Description
Survival from aneurysm-related death.
Time Frame
1 year
Title
Treatment success at 12 months post-procedure
Description
Composite endpoint which includes Technical Success, Procedural Success, and freedom from aneurysm-related mortality
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Target artery patency
Description
Imaging studies (CT Scans, Ultrasound and/or x-rays) are completed yearly to evaluate target artery patency.
Time Frame
Yearly through 5 years
Title
Freedom from all-cause mortality
Description
Clinical evaluations are completed yearly and include bloodwork (WBC, Hemoglobin, Hematocrit, Platelets, BUN [Urea Nitrogen], Creatinine, eGFR), imaging scans (CT scans, Ultrasounds, and/or x-rays) and adverse event evaluation.
Time Frame
Yearly through 5 years
Title
Freedom from reintervention
Description
Clinical evaluations are completed yearly and include bloodwork (WBC, Hemoglobin, Hematocrit, Platelets, BUN [Urea Nitrogen], Creatinine, eGFR), imaging scans (CT scans, Ultrasounds, and/or x-rays) and adverse event evaluation to determine if reintervention with the device is necessary.
Time Frame
Yearly through 5 years
Title
Freedom from endoleak
Description
Imaging studies (CT Scans, Ultrasound and/or x-rays) are completed yearly to evaluate device integrity and any device leaks.
Time Frame
Yearly through 5 years
Title
Freedom from aneurysm dilatation
Description
Imaging studies (CT Scans, Ultrasound and/or x-rays) are completed yearly to evaluate aneurysm size.
Time Frame
Yearly through 5 years
Title
Freedom from serious adverse events (SAE) and major complications
Description
Clinical evaluations are completed yearly and include bloodwork (WBC, Hemoglobin, Hematocrit, Platelets, BUN [Urea Nitrogen], Creatinine, eGFR), imaging scans (CT scans, Ultrasounds, and/or x-rays) and adverse event evaluation.
Time Frame
Yearly through 5 years
Title
Freedom from aneurysm rupture and conversion to open repair
Description
Clinical evaluations are completed yearly and include bloodwork (WBC, Hemoglobin, Hematocrit, Platelets, BUN [Urea Nitrogen], Creatinine, eGFR), imaging scans (CT scans, Ultrasounds, and/or x-rays) and adverse event evaluation to determine if aneurysm stability.
Time Frame
Yearly through 5 years
Title
Freedom from stent graft migration and branch device migration
Description
Imaging studies (CT Scans, Ultrasound and/or x-rays) are completed yearly to evaluate device integrity and any device leaks.
Time Frame
Yearly through 5 years
Title
Freedom from major stroke
Description
Clinical evaluations are completed yearly and include bloodwork (WBC, Hemoglobin, Hematocrit, Platelets, BUN [Urea Nitrogen], Creatinine, eGFR), imaging scans (CT scans, Ultrasounds, and/or x-rays) and adverse event evaluation.
Time Frame
Yearly through 5 years
Title
Freedom from paralysis
Description
Clinical evaluations are completed yearly and include bloodwork (WBC, Hemoglobin, Hematocrit, Platelets, BUN [Urea Nitrogen], Creatinine, eGFR), imaging scans (CT scans, Ultrasounds, and/or x-rays) and adverse event evaluation.
Time Frame
Yearly through 5 years
Title
Freedom from onset permanent hemodialysis
Description
Clinical evaluations are completed yearly and include bloodwork (WBC, Hemoglobin, Hematocrit, Platelets, BUN [Urea Nitrogen], Creatinine, eGFR), imaging scans (CT scans, Ultrasounds, and/or x-rays) and adverse event evaluation.
Time Frame
Yearly through 5 years
Title
Freedom from amputation
Description
Clinical evaluations are completed yearly and include bloodwork (WBC, Hemoglobin, Hematocrit, Platelets, BUN [Urea Nitrogen], Creatinine, eGFR), imaging scans (CT scans, Ultrasounds, and/or x-rays) and adverse event evaluation.
Time Frame
Yearly through 5 years
Title
Freedom from bowel infarction
Description
Clinical evaluations are completed yearly and include bloodwork (WBC, Hemoglobin, Hematocrit, Platelets, BUN [Urea Nitrogen], Creatinine, eGFR), imaging scans (CT scans, Ultrasounds, and/or x-rays) and adverse event evaluation.
Time Frame
Yearly through 5 years
Title
Freedom from loss of target vessel patency
Description
Imaging studies (CT Scans, Ultrasound and/or x-rays) are completed yearly to evaluate device integrity and any device leaks.
Time Frame
Yearly through 5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
TAAA STUDY ARM Inclusion Criteria: Presence of TAAA in: Men with TAAA greater than or equal to 6 cm in diameter Women with TAAA greater than or equal to 5 cm in diameter Men with TAAA larger than 5 cm in diameter and enlarging at a rate of more than 10mm/year Women with TAAA larger than 4.5 cm in diameter and enlarging at a rate of more than 10mm/year or Men or women with TAAA and an iliac artery aneurysm greater than or equal to 4 cm in diameter Life expectancy more than 2 years Ability to give informed consent, complete pre-treatment assessments and comply with the follow-up schedule per protocol Suitable arterial anatomy for endovascular TAAA repair with "TAAA device": Proximal aortic landing zone: ≥ 20mm long ≤ 40mm and ≥ 20mm diameter in parallel aorta free from circumferential thrombus ≤ 60 degrees angulation Mesenteric/renal aortic diameter ≥ 20mm Mesenteric arteries: ≥ 10mm long segment of healthy artery for branch attachment Diameter ≥ 4mm and ≤ 12mm Absence of aberrant or early branching, aneurysm or dissection Renal arteries: ≥ 10mm long segment of healthy artery for branch attachment Diameter ≥ 4mm and ≤ 8mm Absence of aberrant or early branching, aneurysm or dissection Iliac artery access: ≥ 6mm diameter, and absence of severe calcification and tortuosity Or, planned creation of surgical conduit for TAAA device delivery For patients with associated common iliac artery aneurysms (>20mm diameter), adequate internal and external iliac artery landing zones and common iliac artery luminal diameter (for iliac branch device use): ≥ 10mm long segment of healthy internal iliac artery for branch attachment Internal iliac diameter ≥ 5mm and ≤ 12mm External iliac diameter ≥ 6mm diameter, and absence of severe calcification and tortuosity Minimum common iliac artery luminal diameter ≥ 14mm Or, in patients with bilateral common iliac artery aneurysms without suitable anatomy, planned surgical bypass to maintain patency of at least one internal iliac artery Patients deemed high risk for open repair (meeting one, or more, of the following criteria): Age ≥ 65 year Cardiac disease: CAD (history of MI or angina with positive stress test and not revascularizable) LV Ejection fraction < 40% Symptomatic CHF (NYHC Class II, III, or IV) Pulmonary disease: Home oxygen therapy FEV1 < 1.2 l/s Vital capacity < 50% predicted PaCO2 > 45 mm Hg or < 60 mm Hg Renal disease: ESRD on dialysis eGFR < 60 Prior aortic surgery Hostile abdomen Portal hypertension (ascites or varices) Coagulopathy AORTIC ARCH STUDY ARM Inclusion Criteria: Presence of aortic arch aneurysm in: Men with aortic arch aneurysm greater than or equal to 6 cm in diameter, or Women with aortic arch aneurysm greater than or equal to 5 cm in diameter, or Men with aortic arch aneurysm larger than 5 cm in diameter and enlarging at a rate of more than 10 mm/year, or Women with aortic arch aneurysm larger than 4.5 cm in diameter and enlarging at a rate of more than 10 mm/year, or Saccular aortic arch aneurysms deemed at significant risk for rupture based upon physician interpretation Life expectancy more than 2 years Ability to give informed consent, complete pre-treatment assessments and comply with the follow-up schedule per protocol. Suitable arterial anatomy for endovascular aortic arch repair with "Aortic Arch Device": Aneurysm of the aortic arch beginning distal to the native coronary arteries or any patent coronary artery bypass Proximal aortic landing zone: Native aorta or surgical graft ≥ 20 mm long ≤ 42 mm and ≥ 20 mm diameter in parallel aorta free from circumferential thrombus Distal aortic landing zone: Native aorta or surgical graft ≥ 20 mm long ≤ 42 mm and ≥ 20 mm diameter in parallel aorta free from circumferential thrombus ≥ 50mm length from native coronary arteries or patent coronary bypass graft to innominate artery Adequate supra-aortic trunk branch landing zone(s): Innominate artery (if applicable): Native vessel or surgical graft Diameter: 8-22mm Length of sealing zone ≥10mm Acceptable tortuosity Absence of dissection in landing zone Left (or right) common carotid artery (if applicable): Native vessel or surgical graft Diameter 6-16mm Length of sealing zone ≥10mm Acceptable tortuosity Absence of dissection in landing zone Left (or right) subclavian artery (if applicable): Native vessel or surgical graft Diameter: 5-20mm Length of sealing zone ≥10mm Acceptable tortuosity Absence of dissection in landing zone Iliac artery access: ≥ 6mm diameter, and absence of severe calcification and tortuosity Or, planned creation of surgical conduit for TAAA device delivery Patients deemed high risk for open surgical aortic arch repair based upon consensus of both a qualified cardiac surgeon and a qualified vascular surgeon and meeting one, or more, of the following criteria): Age > 70 years-old Prior ascending or aortic arch repair Multiple (≥2) median sternotomies Ischemic cardiomyopathy with multi-level coronary artery disease and/or positive stress test Chronic pulmonary disease with FEV1 < 1500ml Chronic kidney disease with eGFR ≤ 60 ml/kg/hr Large aneurysm abutting the sternotomy Severe deconditioning or immobility Prior cervical irradiation Other medical condition associated with prohibitive high risk with open repair based upon multidisciplinary consensus (cardiac surgery and vascular surgery) APPLIES TO BOTH STUDY ARMS Exclusion Criteria: Rupture, with hypotension (systolic bp < 90). Pregnancy or breastfeeding. Unwillingness or inability to comply with the follow up schedule. Serious systemic or groin infection. Uncorrectable coagulopathy. Age < 18 years. Mycotic aneurysm. Known degenerative connective tissue disease, e.g., Marfan or Ehler-Danlos Syndrome (unless proximal implantation is into a previously placed surgical graft). Known sensitivities or allergies to stainless steel, nitinol, polyester, solder (tin, silver), polypropylene, urethane or gold. Participation in another in another investigational device or drug study within 1 year of treatment. Unrelated concomitant major surgical or interventional procedure(s) within 30 days of treatment date (with the exception of staged procedures planned as part of treatment) Body habitus that would inhibit X-ray visualization of the aorta. Acute aortic dissection Patients able and willing to be treated with a commercially available device or a device being evaluated in a manufacturer-sponsored pivotal study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Darren Schneider, MD
Phone
215-614-0243
Email
Darren.Schneider@Pennmedicine.upenn.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Kiera Zehner
Phone
(412) 737-2572
Email
kiera.zehner@pennmedicine.upenn.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Darren Schneider, MD
Organizational Affiliation
University of Pennsylvania
Official's Role
Principal Investigator
Facility Information:
Facility Name
New York Presbyterian Hospital
City
New York
State/Province
New York
ZIP/Postal Code
10022
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Hospital of the University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Darren Schneider, MD
Phone
215-614-0243
Email
darren.schneider@pennmedicine.upenn.edu
First Name & Middle Initial & Last Name & Degree
Kiera Zehner
Phone
(412) 737-2572
Email
kiera.zehner@pennmedicine.upenn.edu
First Name & Middle Initial & Last Name & Degree
Darren Schneider, MD

12. IPD Sharing Statement

Citations:
PubMed Identifier
28527678
Citation
Meltzer AJ, Connolly PH, Ellozy S, Schneider DB. Patient-reported Quality of Life after Endovascular Repair of Thoracoabdominal Aortic Aneurysms. Ann Vasc Surg. 2017 Oct;44:164-170. doi: 10.1016/j.avsg.2017.04.009. Epub 2017 May 17.
Results Reference
result
PubMed Identifier
28259569
Citation
Stern JR, Ellozy SH, Connolly PH, Meltzer AJ, Schneider DB. Utility and safety of axillary conduits during endovascular repair of thoracoabdominal aneurysms. J Vasc Surg. 2017 Sep;66(3):705-710. doi: 10.1016/j.jvs.2016.12.107. Epub 2017 Mar 1.
Results Reference
result
PubMed Identifier
30080733
Citation
Schneider DB, Agrusa CJ, Ellozy SH, Connolly PH, Meltzer AJ, Graham AR, Michelassi F. Analysis of the Learning Curve and Patient Outcomes of Endovascular Repair of Thoracoabdominal Aortic Aneurysms Using Fenestrated and Branched Stent Grafts: Prospective, Nonrandomized, Single-center Physician-sponsored Investigational Device Exemption Clinical Study. Ann Surg. 2018 Oct;268(4):640-649. doi: 10.1097/SLA.0000000000002960.
Results Reference
result
PubMed Identifier
37395613
Citation
Dias-Neto M, Vacirca A, Huang Y, Baghbani-Oskouei A, Jakimowicz T, Mendes BC, Kolbel T, Sobocinski J, Bertoglio L, Mees B, Gargiulo M, Dias N, Schanzer A, Gasper W, Beck AW, Farber MA, Mani K, Timaran C, Schneider DB, Pedro LM, Tsilimparis N, Haulon S, Sweet MP, Ferreira E, Eagleton M, Yeung KK, Khashram M, Jama K, Panuccio G, Rohlffs F, Mesnard T, Chiesa R, Kahlberg A, Schurink GW, Lemmens C, Gallitto E, Faggioli G, Karelis A, Parodi E, Gomes V, Wanhainen A, Habib M, Colon JP, Pavarino F, Baig MS, Gouveia E Melo REC, Crawford S, Zettervall SL, Garcia R, Ribeiro T, Alves G, Goncalves FB, Kappe KO, Mariko van Knippenberg SE, Tran BL, Gormley S, Oderich GS; International Multicenter Aortic Research Group. Outcomes of Elective and Non-elective Fenestrated-branched Endovascular Aortic Repair for Treatment of Thoracoabdominal Aortic Aneurysms. Ann Surg. 2023 Oct 1;278(4):568-577. doi: 10.1097/SLA.0000000000005986. Epub 2023 Jul 3.
Results Reference
result
PubMed Identifier
37330702
Citation
Finnesgard EJ, Beck AW, Eagleton MJ, Farber MA, Gasper WJ, Lee WA, Oderich GS, Schneider DB, Sweet MP, Timaran CH, Simons JP, Schanzer A; United States Aortic Research Consortium. Severity of acute kidney injury is associated with decreased survival after fenestrated and branched endovascular aortic aneurysm repair. J Vasc Surg. 2023 Oct;78(4):892-901. doi: 10.1016/j.jvs.2023.05.034. Epub 2023 Jun 16.
Results Reference
result
PubMed Identifier
37321524
Citation
Abdelhalim MA, Tenorio ER, Oderich GS, Haulon S, Warren G, Adam D, Claridge M, Butt T, Abisi S, Dias NV, Kolbel T, Gallitto E, Gargiulo M, Gkoutzios P, Panuccio G, Kuzniar M, Mani K, Mees BM, Schurink GW, Sonesson B, Spath P, Wanhainen A, Schanzer A, Beck AW, Schneider DB, Timaran CH, Eagleton M, Farber MA, Modarai B; Multicenter International Aortic Research Group. Multicenter trans-Atlantic experience with fenestrated-branched endovascular aortic repair of chronic post-dissection thoracoabdominal aortic aneurysms. J Vasc Surg. 2023 Oct;78(4):854-862.e1. doi: 10.1016/j.jvs.2023.05.053. Epub 2023 Jun 13.
Results Reference
result
PubMed Identifier
37059239
Citation
Aucoin VJ, Motyl CM, Novak Z, Eagleton MJ, Farber MA, Gasper W, Oderich GS, Mendes B, Schanzer A, Tenorio E, Timaran CH, Schneider DB, Sweet MP, Zettervall SL, Beck AW; U.S. Aortic Research Consortium. Predictors and outcomes of spinal cord injury following complex branched/fenestrated endovascular aortic repair in the US Aortic Research Consortium. J Vasc Surg. 2023 Jun;77(6):1578-1587. doi: 10.1016/j.jvs.2023.01.205. Epub 2023 Apr 13.
Results Reference
result
PubMed Identifier
37051912
Citation
Tenorio ER, Schanzer A, Timaran CH, Schneider DB, Mendes BC, Eagleton MJ, Farber MA, Parodi FE, Gasper WJ, Beck AW, Sweet MP, Huang Y, Oderich GS; U.S. Fenestrated and Branched Aortic Research Consortium. Mid-term Renal and Mesenteric Artery Outcomes During Fenestrated and Branched Endovascular Aortic Repair for Complex Abdominal and Thoracoabdominal Aortic Aneurysms in the United States Aortic Research Consortium. Ann Surg. 2023 Oct 1;278(4):e893-e902. doi: 10.1097/SLA.0000000000005859. Epub 2023 Apr 13.
Results Reference
result
PubMed Identifier
36948277
Citation
Tenorio ER, Schanzer A, Timaran CH, Schneider DB, Mendes BC, Eagleton MJ, Farber MA, Parodi FE, Gasper WJ, Beck AW, Sweet MP, Zettervall SL, Huang Y, Oderich GS; U.S. Fenestrated and Branched Aortic Research Consortium. Effect of bridging stent graft selection for directional branches on target artery outcomes of fenestrated-branched endovascular aortic repair in the United States Aortic Research Consortium. J Vasc Surg. 2023 Jul;78(1):10-28.e3. doi: 10.1016/j.jvs.2023.03.025. Epub 2023 Mar 21.
Results Reference
result
PubMed Identifier
36921644
Citation
Heslin RT, Blakeslee-Carter J, Novak Z, Eagleton MJ, Farber MA, Oderich GS, Schanzer A, Timaran CH, Schneider DB, Sweet MP, Beck AW. Aneurysm extent-based mortality differences in complex endovascular repair of thoracoabdominal aneurysms in the Vascular Quality Initiative and the United States Aortic Research Consortium. J Vasc Surg. 2023 Jul;78(1):1-9.e3. doi: 10.1016/j.jvs.2023.02.020. Epub 2023 Mar 14.
Results Reference
result
PubMed Identifier
36731757
Citation
Dias-Neto M, Tenorio ER, Huang Y, Jakimowicz T, Mendes BC, Kolbel T, Sobocinski J, Bertoglio L, Mees B, Gargiulo M, Dias N, Schanzer A, Gasper W, Beck AW, Farber MA, Mani K, Timaran C, Schneider DB, Pedro LM, Tsilimparis N, Haulon S, Sweet M, Ferreira E, Eagleton M, Yeung KK, Khashram M, Vacirca A, Lima GB, Baghbani-Oskouei A, Jama K, Panuccio G, Rohlffs F, Chiesa R, Schurink GW, Lemmens C, Gallitto E, Faggioli G, Karelis A, Parodi E, Gomes V, Wanhainen A, Dean A, Colon JP, Pavarino F, E Melo RG, Crawford S, Garcia R, Ribeiro T, Kappe KO, van Knippenberg SEM, Tran BL, Gormley S, Oderich GS; International Aortic Research Consortium. Comparison of single- and multistage strategies during fenestrated-branched endovascular aortic repair of thoracoabdominal aortic aneurysms. J Vasc Surg. 2023 Jun;77(6):1588-1597.e4. doi: 10.1016/j.jvs.2023.01.188. Epub 2023 Jan 31.
Results Reference
result
PubMed Identifier
36257344
Citation
Chamseddin K, Timaran CH, Oderich GS, Tenorio ER, Farber MA, Parodi FE, Schneider DB, Schanzer A, Beck AW, Sweet MP, Zettervall SL, Mendes B, Eagleton MJ, Gasper WJ; U.S. Aortic Research Consortium. Comparison of upper extremity and transfemoral access for fenestrated-branched endovascular aortic repair. J Vasc Surg. 2023 Mar;77(3):704-711. doi: 10.1016/j.jvs.2022.10.009. Epub 2022 Oct 17.
Results Reference
result
PubMed Identifier
34954272
Citation
Zettervall SL, Tenorio ER, Schanzer A, Oderich GS, Timaran CH, Schneider DB, Eagleton M, Farber MA, Gasper WJ, Beck AW, Sweet MP; U.S. Fenestrated and Branched Aortic Research Consortium. Secondary interventions after fenestrated/branched aneurysm repairs are common and nondetrimental to long-term survival. J Vasc Surg. 2022 May;75(5):1530-1538.e4. doi: 10.1016/j.jvs.2021.11.074. Epub 2021 Dec 23.
Results Reference
result
PubMed Identifier
33775747
Citation
Edman NI, Schanzer A, Crawford A, Oderich GS, Farber MA, Schneider DB, Timaran CH, Beck AW, Eagleton M, Sweet MP; U.S. Fenestrated and Branched Aortic Research Consortium. Sex-related outcomes after fenestrated-branched endovascular aneurysm repair for thoracoabdominal aortic aneurysms in the U.S. Fenestrated and Branched Aortic Research Consortium. J Vasc Surg. 2021 Sep;74(3):861-870. doi: 10.1016/j.jvs.2021.02.046. Epub 2021 Mar 26.
Results Reference
result
PubMed Identifier
33262091
Citation
Timaran CH, Oderich GS, Tenorio ER, Farber MA, Schneider DB, Schanzer A, Beck AW, Sweet MP; Aortic Research Consortium. Expanded Use of Preloaded Branched and Fenestrated Endografts for Endovascular Repair of Complex Aortic Aneurysms. Eur J Vasc Endovasc Surg. 2021 Feb;61(2):219-226. doi: 10.1016/j.ejvs.2020.11.001. Epub 2020 Nov 28.
Results Reference
result
PubMed Identifier
33227467
Citation
Banga P, Oderich GS, Farber M, Reis de Souza L, Tenorio ER, Timaran C, Schneider DB, Baumgardt Barbosa Lima G, Barreira Marcondes G, Timaran D. Impact of Number of Vessels Targeted on Outcomes of Fenestrated-Branched Endovascular Repair for Complex Abdominal Aortic Aneurysms. Ann Vasc Surg. 2021 Apr;72:98-105. doi: 10.1016/j.avsg.2020.09.063. Epub 2020 Nov 21.
Results Reference
result
PubMed Identifier
32882346
Citation
Aucoin VJ, Eagleton MJ, Farber MA, Oderich GS, Schanzer A, Timaran CH, Schneider DB, Sweet MP, Beck AW. Spinal cord protection practices used during endovascular repair of complex aortic aneurysms by the U.S. Aortic Research Consortium. J Vasc Surg. 2021 Jan;73(1):323-330. doi: 10.1016/j.jvs.2020.07.107. Epub 2020 Aug 31.
Results Reference
result
PubMed Identifier
32640318
Citation
Kitpanit N, Ellozy SH, Connolly PH, Agrusa CJ, Lichtman AD, Schneider DB. Risk factors for spinal cord injury and complications of cerebrospinal fluid drainage in patients undergoing fenestrated and branched endovascular aneurysm repair. J Vasc Surg. 2021 Feb;73(2):399-409.e1. doi: 10.1016/j.jvs.2020.05.070. Epub 2020 Jul 5.
Results Reference
result
PubMed Identifier
31882309
Citation
Tenorio ER, Oderich GS, Farber MA, Schneider DB, Timaran CH, Schanzer A, Beck AW, Motta F, Sweet MP; U.S. Fenestrated and Branched Aortic Research Consortium Investigators. Outcomes of endovascular repair of chronic postdissection compared with degenerative thoracoabdominal aortic aneurysms using fenestrated-branched stent grafts. J Vasc Surg. 2020 Sep;72(3):822-836.e9. doi: 10.1016/j.jvs.2019.10.091. Epub 2019 Dec 25.
Results Reference
result
PubMed Identifier
31394224
Citation
Agrusa CJ, Connolly PH, Ellozy SH, Schneider DB. Safety and Effectiveness of Percutaneous Axillary Artery Access for Complex Aortic Interventions. Ann Vasc Surg. 2019 Nov;61:326-333. doi: 10.1016/j.avsg.2019.05.046. Epub 2019 Aug 5.
Results Reference
result

Learn more about this trial

Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts

We'll reach out to this number within 24 hrs